

GERON CORPORATION

Form 8-K

March 11, 2002

Table of Contents

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
SECURITIES AND EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 6, 2002

GERON CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

0-20859
(Commission File Number)

75-2287752
(IRS Employer
Identification Number)

230 Constitution Drive
Menlo Park, California
(Address of principal executive offices)

(650) 473-7700
(Registrant's telephone number, including area code)

94025
(Zip Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

Item 5. Other Events.

Item 7. Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 5. Other Events.

On March 6, 2002, Geron Corporation, a Delaware corporation (the Company), announced that it has acquired patents related to oligonucleotides containing phosphoramidate backbone linkages from Lynx Therapeutics, Inc.

The Company's press release announcing the acquisition is filed as an exhibit to this Current Report on Form 8-K. The summary description of the event is qualified in its entirety by reference to the document filed as an exhibit hereto.

Table of Contents

Item 7. Exhibits.

Exhibits

99.1 Press Release dated March 6, 2002.

3

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: March 8, 2002

By: /s/ William D. Stempel

Name: William D. Stempel
Title: Vice President and General Counsel

4

Table of Contents

EXHIBIT INDEX

Exhibits

99.1 Press Release dated March 6, 2002.

5